Filtrer vos résultats
- 3
- 3
- 3
- 2
- 1
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 3
- 3
- 3
- 3
- 3
- 3
- 3
- 3
- 3
- 3
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
triés par
|
|
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trialLancet Oncology, 2021, 22 (10), pp.1378-1390. ⟨10.1016/S1470-2045(21)00428-9⟩
Article dans une revue
hal-03604926v1
|
||
|
Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experienceBlood, 2021, 138 (25), pp.2686-2695. ⟨10.1182/blood.2021011285⟩
Article dans une revue
hal-03578209v1
|
||
|
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 studyThe Lancet, 2019, 394 (10192), pp.29-38. ⟨10.1016/S0140-6736(19)31240-1⟩
Article dans une revue
hal-03605015v1
|